Abstract

Endothelial cells (ECs) are an important component of the tumor microenvironment, playing key roles in tumor development and progression that span from angiogenesis to immune regulation and drug resistance. Heterotypic tumor spheroids are one of the most widely used in vitro tumor microenvironment models, presenting improved recapitulation of tumor microenvironments compared to 2D cultures, in a simple and low-cost setup. Heterotypic tumor spheroid models incorporating endothelial cells have been proposed but present multiple limitations, such as the short culture duration typically obtained, the use of animal-derived matrices, and poor reproducibility; the diversity of culture conditions employed hinders comparison between studies and standardization of relevant culture parameters. Herein, we developed long-term cultures of triple heterotypic spheroids composed of the HCC1954 tumor cell line, human fibroblasts, and ECs. We explored culture parameters potentially relevant for EC maintenance, such as tumor cell line, seeding cell number, cell ratio, and agitation vs. static culture. In HCC1954-based spheroids, we observed maintenance of viable EC for up to 1 month of culture in agitation, with retention of the identity markers CD31 and von Willebrand factor. At the optimized tumor cell:fibroblast:EC ratio of 1:3:10, HCC1954-based spheroids had a higher EC area/total spheroid area at 1 month of culture than the other cell ratios tested. EC maintenance was tumor cell line-dependent, and in HCC1954-based spheroids it was also dependent on the presence of fibroblasts and agitation. Moreover, vascular endothelial growth factor (VEGF) supplementation was not required for maintenance of EC, as the factor was endogenously produced. ECs co-localized with fibroblasts, which accumulated preferentially in the core of the spheroids and secreted EC-relevant extracellular matrix proteins, such as collagen I and IV. This simple model setup does not rely on artificial or animal-derived scaffolds and can serve as a useful tool to explore the culture parameters influencing heterotypic spheroids, contributing to model standardization, as well as to explore molecular cross talk of ECs within the tumor microenvironment, and potentially its effects on drug response.

Highlights

  • The tumor microenvironment (TME) impacts cancer progression, invasion, metastasis, and drug resistance (Quail and Joyce, 2013; Klemm and Joyce, 2015)

  • Endothelial cells (ECs) play a major role in tumor angiogenesis, being critical in fueling tumor growth and progression (Hanahan and Coussens, 2012)

  • EC-targeting therapy, such as anti-angiogenic strategies, have shown promising results yet have failed to reach in the clinics the success observed in animal models (Ye, 2016)

Read more

Summary

Introduction

The tumor microenvironment (TME) impacts cancer progression, invasion, metastasis, and drug resistance (Quail and Joyce, 2013; Klemm and Joyce, 2015). Therapeutic agents targeting tumor angiogenesis, such as anti-VEGF or tyrosine kinase inhibitors, have been developed, initially with promising results; these therapies showed limited clinical success due to drug resistance and high toxicity, not predicted by the preclinical models employed (Bergers and Hanahan, 2008; Jain, 2014; Aalders et al, 2017). Multiple studies suggested that ECs are modulated by the TME, acquiring genetic abnormalities and distinct transcriptional programs These changes contribute to anti-angiogenic therapy resistance and to functions behind the classical angiogenic role that are not observed in normal ECs. Tumor-associated ECs are recognized as key mediators of immune regulation within the TME (Nagl et al, 2020), tumor metastization, and drug resistance mechanisms (Hida et al, 2018; Maishi et al, 2019). Well-defined and characterized cell models, in which EC interactions within the TME in different stages of tumor progression can be recapitulated, constitute a preclinical need

Objectives
Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call